All included treatments result ed in ADHD improvement .
On the basis of this literature review , a consistent pattern of improvement in pediatric ADHD patients ' core symptoms emerged across studies , study design s , and recommended treatment approaches .
OBJECTIVE The 2011 American Academy of Pediatrics attention-deficit/hyperactivity disorder ( ADHD ) guideline emphasizes monitoring and measuring outcomes of children diagnosed with ADHD ; however , recommendations for how to measure improvement are less clear .
A long-term goal was to develop an outcome measure that assesses the quality of care for children with ADHD .
As a first step in that process , we conducted a literature synthesis on the efficacy and effectiveness of guideline -recommended ADHD treatments on patient outcomes .
Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
OBJECTIVE The aim of this study was to assess the effectiveness and safety of lisdexamfetamine dimesylate ( LDX ) in children with attention-deficit/hyperactivity disorder ( ADHD ) . METHOD This was a 7-week , open-label study evaluating 20 , 30 , 40 , 50 , 60 , or 70 mg/day LDX in 318 children aged 6 - 12 years with ADHD . The ADHD Rating Scale IV ( ADHD-RS-IV ) was the primary efficacy assessment . Secondary measures included the Clinical Global Impressions-Improvement ( CGI-I ) , Expression and Emotion Scale for Children ( EESC ) , and Behavior Rating Inventory of Executive Function ( BRIEF ) . Safety assessment s included  treatment-emergent adverse events ( TEAEs ) , vital signs , and electrocardiograms .  RESULTS At end point , mean ( st and ard deviation [ SD ] ) improvement from baseline in ADHD-RS-IV total score was 28.6 ( 10.9 ) ( p < 0.0001 ) . Most subjects ( 89.9 % ) were rated " improved " ( i.e. , CGI-I 1 or 2 ) . Improvements from baseline were observed in the EESC total and subscale scores ( p < or = 0.0002 ) . LDX treatment result ed in significant improvement on the Global Executive Composite , Behavioral Regulation , and Metacognition indices of the BRIEF ( p < 0.0001 ) . TEAEs ( incidences > or = 10 % ) were decreased appetite , decreased weight , irritability , insomnia , headache , upper abdominal pain , and initial insomnia . CONCLUSIONS LDX was effective and generally well tolerated with a safety profile consistent with long-acting stimulant use . There was overall improvement in ADHD symptoms and executive function measures and no worsening of emotional expression measures . TRIAL REGISTRATION clinical trials.gov Identifier : NCT00500071
All included treatments result ed in ADHD improvement .
On the basis of this literature review , a consistent pattern of improvement in pediatric ADHD patients ' core symptoms emerged across studies , study design s , and recommended treatment approaches .
OBJECTIVE The 2011 American Academy of Pediatrics attention-deficit/hyperactivity disorder ( ADHD ) guideline emphasizes monitoring and measuring outcomes of children diagnosed with ADHD ; however , recommendations for how to measure improvement are less clear .
A long-term goal was to develop an outcome measure that assesses the quality of care for children with ADHD .
As a first step in that process , we conducted a literature synthesis on the efficacy and effectiveness of guideline -recommended ADHD treatments on patient outcomes .